|
- GSK PLC and Sanofi SA on Friday reported positive results against the Omicron variant of Covid-19 from their vaccine in a placebo-controlled trial.
The trial evaluated an adjuvanted bivalent D614 and Beta vaccine candidate. It demonstrated an efficacy of 64.7% against symptomatic Covid-19 and 72% efficacy in Omicron-confirmed symptomatic cases.
‘Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,’ the companies noted.
Over 13,000 people participated in stage two of the phase three Covid vaccine VAT08 trial. Throughout stage 1 and stage 2 of the VAT08 trial - around 23,000 participants in total - the Sanofi-GSK vaccine demonstrated a favorable safety and tolerability profile.
‘Our vaccine candidate has the potential to make an important contribution to public health as the pandemic evolves further. We are looking forward to the discussions with regulatory authorities with the aim of making our vaccine candidate available later this year,’ said Roger Connor, president of GSK Vaccines.
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
